Expanded access in the Netherlands: prescribing unregistered medicine 41 38. Medicines and Healthcare products Regulatory Agency. Guidance Apply for the early access to medicines scheme (EAMS). https://www.gov. uk/guidance/apply-for-the-early-access-tomedicines-scheme-eams#fees 39. Banerjee R, Prasad V. Are Observational, Real-World Studies Suitable to Make Cancer Treatment Recommendations? JAMA Netw Open. 2020;3(7):e2012119-e2012119. doi:10.1001/ jamanetworkopen.2020.12119 40. Viele K, Berry S, Neuenschwander B, et al. Use of historical control data for assessing treatment effects in clinical trials. Pharm Stat. 2014;13(1):41-54. doi:10.1002/pst.1589 41. Polak TB, Bunnik EM. Financial considerations in expanded access policy for gene therapies: A tough nut to crack? Mol Ther. 2021;29(6):20212021. doi:10.1016/j.ymthe.2021.04.030 42. Borysowski J, Górski A. Ethics framework for treatment use of investigational drugs. BMC Med Ethics. 2020;21(1):116-116. doi:10.1186/ s12910-020-00560-9 43. Bunnik EM, Aarts N. A Model for Communication About Longshot Treatments in the Context of Early Access to Unapproved, Investigational Drugs. Am J Bioeth AJOB. 2018;18(1):34-36. doi :10.1080/15265161.2017.1401170 44. Chapman CR, Shearston JA, Folkers KM, Redman BK, Caplan A, Bateman-House A. Single-Patient Expanded Access Requests: IRB Professionals’ Experiences and Perspectives. AJOB Empir Bioeth. 2019;10(2):88-99. doi:10.1080/232945 15.2019.1577192 45. Redman BK, Bateman-House AS. Institutional Review Boards as Arbiters of Expanded Access to Unapproved Drugs: Time for a Change? Ther Innov Regul Sci. 2016;50(4):515-516. doi:10.1177/2168479016628918 46. Caplan AL, Bateman-House A, Waldstreicher J. Compassionate Use: A Modest Proposal. Am Soc Clin Oncol Educ Book Am Soc Clin Oncol Annu Meet. 2016;35:e2-4. doi:10.1200/EDBK_156130 47. Caplan AL, Ray A. The Ethical Challenges of Compassionate Use. JAMA. 2016;315(10):979980. doi:10.1001/jama.2016.0416 48. Serris A, Pouvaret A, Loiseau C, et al. Pritelivir for recurrent aciclovir-resistant herpes simplex virus 2 infections in immunocompromised patients. J Antimicrob Chemother. 2022;77(8):2303-2305. doi:10.1093/jac/ dkac165 49. Maughan NM, Kim H, Hao Y, et al. Initial experience and lessons learned with implementing Lutetium-177-dotatate radiopharmaceutical therapy in a radiation oncology-based program. Brachytherapy. 2021;20(1):237-247. 50. Hordijk L. Reconstructie Lutetium-Octreotaat | Nederlands Tijdschrift Voor Geneeskunde. Vol D3744.; 2019. https://www.ntvg.nl/artikelen/ reconstructie-lutetium-octreotaat/volledig 51. Wald A, Corey L, Timmler B, et al. Helicaseprimase inhibitor pritelivir for HSV-2 infection. N Engl J Med. 2014;370(3):201-210. doi:10.1056/ NEJMoa1301150 52. Widener RW, Whitley RJ. Herpes simplex virus. In: Handbook of Clinical Neurology. Vol 123. Elsevier; 2014:251-263. doi:10.1016/B978-0444-53488-0.00011-0 53. Birkmann A, Bonsmann S, Kropeit D, et al. Discovery, Chemistry, and Preclinical Development of Pritelivir, a Novel Treatment Option for Acyclovir-Resistant Herpes Simplex Virus Infections. J Med Chem. 2022;65(20):1361413628. doi:10.1021/acs.jmedchem.2c00668 54. Wald A, Timmler B, Magaret A, et al. Effect of Pritelivir Compared With Valacyclovir on Genital HSV-2 Shedding in Patients With Frequent Recurrences: A Randomized Clinical Trial. JAMA. 2016;316(23):2495. doi:10.1001/ jama.2016.18189 55. Keam SJ. Tabelecleucel: First Approval. Mol Diagn Ther. 2023;27(3):425-431. doi:10.1007/ s40291-023-00648-z 56. Choquet S, Chaganti S, Uttenthal B, et al. Demographics and treatment outcomes in patients with EBV+ PTLD treated with offthe-shelf EBV-specific CTL under an ongoing expanded access program in Europe: First analyses. https://doi.org/101200/JCO20224016_ suppl7530. 2022;40(16_suppl):7530-7530. doi:10.1200/JCO.2022.40.16_SUPPL.7530
RkJQdWJsaXNoZXIy MTk4NDMw